Professor Carolyn Taylor
Carolyn Taylor
BM BCh (oxon) MA MRCP FRCR DPhil
Professor, Clinical Research Fellow and Honorary Consultant Oncologist
Carolyn Taylor is a consultant clinical oncologist and professor of oncology. She studied medicine at Oxford University. Her clinical training was in general medicine and then clinical oncology. She gained Fellowship of the Royal College of Radiologists in 2004.
Since then she has worked as a clinical research fellow at the Clinical Trial Service Unit, doing research alongside clinical work. She completed her DPhil on the risk of heart disease after breast cancer radiotherapy in 2008.
She now provides clinical leadership in large international collaborations including oncologists, epidemiologists, statisticians and cancer registry staff.
She works in the Early Breast Cancer Trialists’ Collaborative Group on trials of surgery and radiotherapy.
She is Principal Investigator on a Cancer Research UK research program on the benefits and risks of cancer treatments. This programme combines information from high quality datasets to produce estimates of benefits and risks for use by oncologists in the clinic today.
Recent publications
-
Radiotherapy to regional nodes in early breast cancer: Individual-patient-data meta-analysis of 14,324 women in 16 trial
Journal article
Taylor CAROLYN., (2023), The Lancet
-
Breast Cancer Mortality in 500,000 Women Diagnosed with Early Invasive Breast Cancer in England, 1993-2015: Population Based Observational Cohort Study
Journal article
Taylor C. et al, (2023), BMJ: British Medical Journal
-
Proton Beam Therapy in Breast Cancer Patients: The UK PARABLE Trial is Recruiting
Journal article
Kirby AM. et al, (2023), Clinical Oncology
-
Exposure of the heart and cardiac valves in women irradiated for breast cancer 1970-2009
Journal article
Duane F. et al, (2022), Clinical and Translational Radiation Oncology
-
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Journal article
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) None., (2021), Lancet Oncol, 22, 1139 - 1150